A single center experience with the freestyle bioprosthesis : midterm results at the Québec Heart Institute

DC FieldValueLanguage
dc.contributor.authorDagenais, François-
dc.contributor.authorCartier, Paul C.-
dc.contributor.authorDumesnil, Jean G.-
dc.contributor.authorPibarot, Philippe-
dc.contributor.authorLemieux, Michel-
dc.contributor.authorRaymond, Gilles-
dc.contributor.authorDesaulniers, Denis-
dc.contributor.authorPerron, Jean-
dc.contributor.authorBauset, Richard-
dc.contributor.authorBaillot, Richard-
dc.contributor.authorDoyle, Daniel-
dc.date.accessioned2016-07-12T12:25:56Z-
dc.date.available10000-01-01-
dc.date.issued2001-10-01-
dc.identifier.issn1043-0679fr_CA
dc.identifier.urihttp://hdl.handle.net/20.500.11794/8571-
dc.description.abstractStentless bioprostheses show excellent early hemodynamic performance. However, longevity still remains unknown. This study reports midterm follow-up in 419 patients in which a Freestyle bioprosthesis (Medtronic Heart Valves, Minneapolis, MN) was inserted between January 1993 and January 2000 at the Quebec Heart Institute (Ste-Foy, Québec, Canada). Mean age at implantation was 68.0 +/- 8.2 years. Implantation was subcoronary in 81.9% of the patients, as a root replacement in 16.5%, and as a root inclusion in 1.7%. Mortality at 30 days was 6.2% for the whole cohort (2.8% for isolated subcoronary aortic valve replacement). Female gender, root implantation, valve sizes 19 to 21 mm, previous surgery, a history of stroke and diabetes were identified as predictors of 30-day mortality. Actuarial freedom from all death causes was 81.5% at 7 years; freedom from valve-related deaths 97.0%, and freedom from cardiac deaths 92.7%. Freedom from thromboembolic events was 86.1% at 7 years (55.1% of events were < 30 days). Freedom from endocarditis and hemorrhagic complications were respectively 98.5% and 95.6% at 7 years. Six patients required reoperations for valve explantation: 2 for endocarditis, 2 for structural dysfunction, and 2 for nonstructural dysfunction. Incidence of moderate or severe valve insufficiency at annual echocardiographic follow-up was: discharge: 0.6%; year 1: 0.7%; year 2: 1.3%; year 3: 3.3%; year 4: 3.7%; year 5: 2.6%; year 6: 0%. At 6 years after implantation, mean transvalvular gradient and effective valve orifice area were comparable to the year 1 values. This single center experience with the Medtronic Freestyle prosthesis shows preserved hemodynamic performance and low valve-related complications at midterm.fr_CA
dc.languageengfr_CA
dc.publisherW.B. Saundersfr_CA
dc.subjectAortic valve replacementfr_CA
dc.subjectMidterm resultsfr_CA
dc.subjectStentless valvesfr_CA
dc.titleA single center experience with the freestyle bioprosthesis : midterm results at the Québec Heart Institutefr_CA
dc.typeCOAR1_1::Texte::Périodique::Revue::Contribution à un journal::Article::Article de recherche-
dcterms.bibliographicCitationSeminars in thoracic and cardiovascular surgery, Vol. 13 (4, suppl.1), 156-162 (2001)fr_CA
dc.audienceCardiologuesfr_CA
dc.audienceMédecinsfr_CA
dc.audienceProfesseurs (Enseignement supérieur)fr_CA
dc.audienceÉtudiantsfr_CA
dc.audienceDoctorantsfr_CA
dc.identifier.pubmed11805965fr_CA
dc.subject.rvmProthèses valvulaires cardiaquesfr_CA
dc.subject.rvmHémodynamiquefr_CA
dc.subject.rvmMortalitéfr_CA
rioxxterms.versionVersion of Recordfr_CA
rioxxterms.version_of_recordhttp://www.semthorcardiovascsurg.com/-
rioxxterms.project.funder_namen/afr_CA
bul.rights.periodeEmbargoInfinifr_CA
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
SizeFormat 
Dagenais2001-5682.pdf
595.91 kBAdobe PDF    Request a copy
All documents in CorpusUL are protected by Copyright Act of Canada.